A second international cooperative investigation into tioacetazone side effects.
As part of a large-scale international cooperative investigation into the side effects of thioacetazone-containing regimens in the treatment of tuberculosis, an evaluation has been made of the variation in the frequency of side effects between different countries and between different centres in the same country and of the likely reasons for this variation. In 3 countries patients of different racial origin were under observation in the same hospital. Over a 12-week period of treatment there was considerable variation between the countries and centres in the overall frequency of side effects and of those leading to a major departure from prescribed treatment, the variation being similar for the two thioacetazone-containing regimens and for the streptomycin plus isoniazid control regimen, though at a lower level for the latter. In Malaysia, Singapore, and Trinidad, where different racial groups were under treatment, there was no clear indication that race was an important factor in explaining the differences between countries, except for cutaneous side effects in Trinidad and possibly in Malaysia.It is concluded that the differences in the frequency of side effects to thioacetazone-containing regimens probably result from variation in the closeness of supervision of patients, in the recording and interpretation of side effects, and in environmental factors including the previous use of other medicaments or exposure to sensitizing substances.
D000328:Adult; D000352:Africa, Northern; D000995:Antitubercular Agents / Q000009:adverse effects*; D001208:Asia; D003604:Czechoslovakia; D004342:Drug Hypersensitivity; D005260:Female; D005843:Geography; D006801:Humans; D007391:International Cooperation; D008297:Male; D008875:Middle Aged; D044469:Racial Groups; D013828:Thioacetazone / Q000009:adverse effects*; D014300:Trinidad and Tobago; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000995:Antitubercular Agents; D013828:Thioacetazone